Diagnosis and Management of Onychomycosis Perspectives from a Joint Podiatric Medicine-Dermatology Roundtable

Tracey C. Vlahovic, Warren S. Joseph, Richard K. Scher, Antonella Tosti, Jesse Plasencia, David M. Pariser, Bryan C. Markinson

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Onychomycosis is a fungal infection, and, as such, one of the goals of treatment should be eradication of the infective agent. Despite this, in contrast to dermatologists, many podiatric physicians do not include antifungals in their onychomycosis treatment plans. Before initiating treatment, confirmation of mycologic status via laboratory testing (eg, microscopy with potassium hydroxide preparation, histopathology with periodic acid-Schiff staining, fungal culture, and polymerase chain reaction) is important; however, more podiatric physicians rely solely on clinical signs than do dermatologists. These dissimilarities may be due, in part, to differences between specialties in training, reimbursement patterns, or practice orientation, and to explore these differences further, a joint podiatric medicine-dermatology roundtable was convened. In addition, treatment options have been limited owing to safety concerns with available oral antifungals and relatively low efficacy with previously available topical treatments. Recently approved topical treatments-efinaconzole and tavaborole-offer additional options for patients with mild-to-moderate disease. Debridement alone has no effect on mycologic status, and it is recommended that it be used in combination with an oral or topical antifungal. There is little to no clinical evidence to support the use of lasers or over-the-counter treatments for onychomycosis. After a patient has achieved cure (absence of clinical signs or absence of fungus with minimal clinical signs), lifestyle and hygiene measures, prophylactic/maintenance treatment, and proactive treatment for tinea pedis, including in family members, may help maintain this status.

Original languageEnglish (US)
Pages (from-to)155-162
Number of pages8
JournalJournal of the American Podiatric Medical Association
Volume106
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Onychomycosis
Dermatology
Joints
Medicine
Therapeutics
Tinea Pedis
Physicians
Periodic Acid
Mycoses
Debridement
Hygiene
Life Style
Microscopy
Lasers
Fungi
Staining and Labeling
Safety
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Podiatry
  • Orthopedics and Sports Medicine

Cite this

Diagnosis and Management of Onychomycosis Perspectives from a Joint Podiatric Medicine-Dermatology Roundtable. / Vlahovic, Tracey C.; Joseph, Warren S.; Scher, Richard K.; Tosti, Antonella; Plasencia, Jesse; Pariser, David M.; Markinson, Bryan C.

In: Journal of the American Podiatric Medical Association, Vol. 106, No. 2, 01.03.2016, p. 155-162.

Research output: Contribution to journalReview article

Vlahovic, Tracey C. ; Joseph, Warren S. ; Scher, Richard K. ; Tosti, Antonella ; Plasencia, Jesse ; Pariser, David M. ; Markinson, Bryan C. / Diagnosis and Management of Onychomycosis Perspectives from a Joint Podiatric Medicine-Dermatology Roundtable. In: Journal of the American Podiatric Medical Association. 2016 ; Vol. 106, No. 2. pp. 155-162.
@article{709abc2ebfbc407e9e52202ac7a1f47a,
title = "Diagnosis and Management of Onychomycosis Perspectives from a Joint Podiatric Medicine-Dermatology Roundtable",
abstract = "Onychomycosis is a fungal infection, and, as such, one of the goals of treatment should be eradication of the infective agent. Despite this, in contrast to dermatologists, many podiatric physicians do not include antifungals in their onychomycosis treatment plans. Before initiating treatment, confirmation of mycologic status via laboratory testing (eg, microscopy with potassium hydroxide preparation, histopathology with periodic acid-Schiff staining, fungal culture, and polymerase chain reaction) is important; however, more podiatric physicians rely solely on clinical signs than do dermatologists. These dissimilarities may be due, in part, to differences between specialties in training, reimbursement patterns, or practice orientation, and to explore these differences further, a joint podiatric medicine-dermatology roundtable was convened. In addition, treatment options have been limited owing to safety concerns with available oral antifungals and relatively low efficacy with previously available topical treatments. Recently approved topical treatments-efinaconzole and tavaborole-offer additional options for patients with mild-to-moderate disease. Debridement alone has no effect on mycologic status, and it is recommended that it be used in combination with an oral or topical antifungal. There is little to no clinical evidence to support the use of lasers or over-the-counter treatments for onychomycosis. After a patient has achieved cure (absence of clinical signs or absence of fungus with minimal clinical signs), lifestyle and hygiene measures, prophylactic/maintenance treatment, and proactive treatment for tinea pedis, including in family members, may help maintain this status.",
author = "Vlahovic, {Tracey C.} and Joseph, {Warren S.} and Scher, {Richard K.} and Antonella Tosti and Jesse Plasencia and Pariser, {David M.} and Markinson, {Bryan C.}",
year = "2016",
month = "3",
day = "1",
doi = "10.7547/14-170",
language = "English (US)",
volume = "106",
pages = "155--162",
journal = "Journal of the American Podiatric Medical Association",
issn = "8750-7315",
publisher = "American Podiatric Medical Association",
number = "2",

}

TY - JOUR

T1 - Diagnosis and Management of Onychomycosis Perspectives from a Joint Podiatric Medicine-Dermatology Roundtable

AU - Vlahovic, Tracey C.

AU - Joseph, Warren S.

AU - Scher, Richard K.

AU - Tosti, Antonella

AU - Plasencia, Jesse

AU - Pariser, David M.

AU - Markinson, Bryan C.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Onychomycosis is a fungal infection, and, as such, one of the goals of treatment should be eradication of the infective agent. Despite this, in contrast to dermatologists, many podiatric physicians do not include antifungals in their onychomycosis treatment plans. Before initiating treatment, confirmation of mycologic status via laboratory testing (eg, microscopy with potassium hydroxide preparation, histopathology with periodic acid-Schiff staining, fungal culture, and polymerase chain reaction) is important; however, more podiatric physicians rely solely on clinical signs than do dermatologists. These dissimilarities may be due, in part, to differences between specialties in training, reimbursement patterns, or practice orientation, and to explore these differences further, a joint podiatric medicine-dermatology roundtable was convened. In addition, treatment options have been limited owing to safety concerns with available oral antifungals and relatively low efficacy with previously available topical treatments. Recently approved topical treatments-efinaconzole and tavaborole-offer additional options for patients with mild-to-moderate disease. Debridement alone has no effect on mycologic status, and it is recommended that it be used in combination with an oral or topical antifungal. There is little to no clinical evidence to support the use of lasers or over-the-counter treatments for onychomycosis. After a patient has achieved cure (absence of clinical signs or absence of fungus with minimal clinical signs), lifestyle and hygiene measures, prophylactic/maintenance treatment, and proactive treatment for tinea pedis, including in family members, may help maintain this status.

AB - Onychomycosis is a fungal infection, and, as such, one of the goals of treatment should be eradication of the infective agent. Despite this, in contrast to dermatologists, many podiatric physicians do not include antifungals in their onychomycosis treatment plans. Before initiating treatment, confirmation of mycologic status via laboratory testing (eg, microscopy with potassium hydroxide preparation, histopathology with periodic acid-Schiff staining, fungal culture, and polymerase chain reaction) is important; however, more podiatric physicians rely solely on clinical signs than do dermatologists. These dissimilarities may be due, in part, to differences between specialties in training, reimbursement patterns, or practice orientation, and to explore these differences further, a joint podiatric medicine-dermatology roundtable was convened. In addition, treatment options have been limited owing to safety concerns with available oral antifungals and relatively low efficacy with previously available topical treatments. Recently approved topical treatments-efinaconzole and tavaborole-offer additional options for patients with mild-to-moderate disease. Debridement alone has no effect on mycologic status, and it is recommended that it be used in combination with an oral or topical antifungal. There is little to no clinical evidence to support the use of lasers or over-the-counter treatments for onychomycosis. After a patient has achieved cure (absence of clinical signs or absence of fungus with minimal clinical signs), lifestyle and hygiene measures, prophylactic/maintenance treatment, and proactive treatment for tinea pedis, including in family members, may help maintain this status.

UR - http://www.scopus.com/inward/record.url?scp=85011728860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011728860&partnerID=8YFLogxK

U2 - 10.7547/14-170

DO - 10.7547/14-170

M3 - Review article

C2 - 27031556

AN - SCOPUS:85011728860

VL - 106

SP - 155

EP - 162

JO - Journal of the American Podiatric Medical Association

JF - Journal of the American Podiatric Medical Association

SN - 8750-7315

IS - 2

ER -